Gene · 432
Papers2,727
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,727
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Precision glycoengineered AAV capsids enhance hepatocyte targeting and attenuated immune activation for liver-directed gene therapy. | Biomaterials | 2026 | 42308604 | PubTator, text mining | PubMed |
| Lysosome-Targeting Chimeras (LYTACs): From Modular Design Principles to Diverse Therapeutic Applications. | Chemistry | 2026 | 42298978 | PubTator, text mining | PubMed |
| The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease. | Biomark Res | 2026 | 42298709 | PubTator, text mining | PubMed |
| Molecular Mobility of N-Acetylgalactosamine-Modified Cyclodextrins on a Polyrotaxane for Highly Efficient Liver Targeting of Antibody Chimeras and Genome-Editing Ribonucleoproteins. | Adv Sci (Weinh) | 2026 | 42272347 | PubTator, text mining | PubMed |
| Exploring Clearance Pathways for GalNAc-siRNAs: Insights into Intracellular Kinetics and Therapeutic Implications. | Nucleic Acid Ther | 2026 | 42265847 | PubTator, text mining | PubMed |
| Profiling of extracellular vesicles from primary hepatocytes, organoids, and mash patients identifies cell injury-specific signatures. | Sci Rep | 2026 | 42236744 | PubTator, text mining | PubMed |
| A Galactose-Modified Light-Activatable Persulfurated Arene Fluorescent Probe for Targeted Imaging of Polarity and Viscosity in Liver Cancer Cells. | J Fluoresc | 2026 | 42215758 | PubTator, text mining | PubMed |
| Invitro Hepatic like Differentiation of Umbilical Cord-Derived Mesenchymal Stem Cells through FGF and IGF Factor Preconditioning. | J Stem Cells Regen Med | 2026 | 42212251 | PubTator, text mining | PubMed |
| In vivo base editing of Asgr1 reduces blood lipids in mice. | Mol Ther | 2026 | 42198846 | PubTator, text mining | PubMed |
| Assessment of carbohydrates binding with their receptors on the cell membrane and carbohydrates targeted nano-drugs entry cell. | Colloids Surf B Biointerfaces | 2026 | 42184670 | PubTator, text mining | PubMed |
| The Prognostic Value of Circulating Stem Cells Expressing PD-L1 in Patients with Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2026 | 42183179 | PubTator, text mining | PubMed |
| Quantitative Analysis of Protein-Receptor Binding Using Solid-State Nanopores: Accurate Measurement of Dissociation Constants for KREMEN1 and ASGR1 with SARS-CoV-2 Spike RBD Protein. | J Phys Chem B | 2026 | 42144848 | PubTator, text mining | PubMed |
| Ruthenium Complexes Containing Pyridinyl-Derived Ligands as FLP Catalysts. | Inorg Chem | 2026 | 42130316 | PubTator, text mining | PubMed |
| Efficacy and Safety of Telitacicept in Posttransplant Recurrent IgA Nephropathy. | Kidney Int Rep | 2026 | 42064224 | PubTator, text mining | PubMed |
| Elevated ASGR1 as a Potential Diagnostic Biomarker for Coronary Artery Disease and Predictor of Adverse Outcomes in Hypertensive Patients. | FASEB J | 2026 | 42048115 | PubTator, text mining | PubMed |
| Advanced materials for non-alcoholic fatty liver disease and cardiovascular disease comorbidity therapeutics. | Biomaterials | 2026 | 42001540 | PubTator, text mining | PubMed |
| An Integrated Nanozyme-Exosome Platform for Multi-Targeted Therapy of Metabolic-Associated Steatotic Liver Disease. | Adv Healthc Mater | 2026 | 41968605 | PubTator, text mining | PubMed |
| Glycan-based biological degraders targeting the cytokine immune axis. | Commun Biol | 2026 | 41965429 | PubTator, text mining | PubMed |
| Lanthanide complex-based probes for time-gated luminescence and 19F magnetic resonance imaging of hypochlorous acid in the liver. | Spectrochim Acta A Mol Biomol Spectrosc | 2026 | 41950624 | PubTator, text mining | PubMed |
| Trivalent GalNAc-Mediated Delivery of Cucurbitacin B Overcomes Systemic Toxicity for Potent HCC Chemoradiotherapy. | Biomacromolecules | 2026 | 41950466 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/432/papers?page=2